Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Holdings Lowered by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 87.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,142 shares of the company’s stock after selling 118,079 shares during the quarter. GSA Capital Partners LLP’s holdings in Fulcrum Therapeutics were worth $61,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. National Bank of Canada FI increased its position in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after acquiring an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. Profund Advisors LLC purchased a new position in Fulcrum Therapeutics during the 2nd quarter worth approximately $68,000. Renaissance Technologies LLC acquired a new stake in Fulcrum Therapeutics during the 2nd quarter valued at $82,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Fulcrum Therapeutics in the first quarter valued at $115,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Up 5.8 %

Shares of Fulcrum Therapeutics stock opened at $3.44 on Tuesday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $13.70. The firm has a fifty day simple moving average of $3.41 and a 200-day simple moving average of $6.28. The stock has a market capitalization of $185.55 million, a price-to-earnings ratio of -11.10 and a beta of 2.24.

Analyst Upgrades and Downgrades

A number of brokerages have commented on FULC. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Finally, Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Hold” and an average price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.